- Home
- ACB vs TCRX Comparison
ACB vs TCRX Comparison
Compare ACB & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- TCRX
- Stock Information
- Founded
- ACB 2013
- TCRX 2018
- Country
- ACB Canada
- TCRX United States
- Employees
- ACB N/A
- TCRX N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- TCRX Health Care
- Exchange
- ACB Nasdaq
- TCRX Nasdaq
- Market Cap
- ACB 255.7M
- TCRX 257.5M
- IPO Year
- ACB N/A
- TCRX 2021
- Fundamental
- Price
- ACB $4.20
- TCRX $4.41
- Analyst Decision
- ACB Hold
- TCRX Strong Buy
- Analyst Count
- ACB 1
- TCRX 5
- Target Price
- ACB N/A
- TCRX $11.40
- AVG Volume (30 Days)
- ACB 1.5M
- TCRX 261.6K
- Earning Date
- ACB 11-06-2024
- TCRX 11-12-2024
- Dividend Yield
- ACB N/A
- TCRX N/A
- EPS Growth
- ACB N/A
- TCRX N/A
- EPS
- ACB N/A
- TCRX N/A
- Revenue
- ACB $219,835,671.00
- TCRX $9,362,000.00
- Revenue This Year
- ACB $14.04
- TCRX N/A
- Revenue Next Year
- ACB $8.94
- TCRX $3.10
- P/E Ratio
- ACB N/A
- TCRX N/A
- Revenue Growth
- ACB 13.15
- TCRX N/A
- 52 Week Low
- ACB $2.84
- TCRX $3.73
- 52 Week High
- ACB $9.35
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- ACB 29.02
- TCRX 34.37
- Support Level
- ACB $4.69
- TCRX $5.03
- Resistance Level
- ACB $5.01
- TCRX $6.23
- Average True Range (ATR)
- ACB 0.36
- TCRX 0.43
- MACD
- ACB -0.15
- TCRX -0.05
- Stochastic Oscillator
- ACB 1.88
- TCRX 5.22
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.